Finkelstein E J, Urschel J D, Takita H
School of Medicine, State University of New York at Buffalo, USA.
J Exp Clin Cancer Res. 1997 Dec;16(4):437-9.
Surgical therapy remains the only curative treatment of localized non-small cell lung carcinoma (NSCLC). Yet, the results of surgical therapy leave much to be desired. Recently, neoadjuvant chemotherapy for Stage III NSCLC had become an accepted therapeutic modality. Accordingly, a question is raised regarding the feasibility of neoadjuvant chemotherapy in resectable NSCLC (Stage I and II). In this paper we report three patients, in chronological order, with localized NSCLC who were treated with neoadjuvant chemotherapy. Neoadjuvant chemotherapy was given to the first case with poor pulmonary functions. Decrease in size of the tumor made it possible for him to undergo a more conservative lung resection. In the second case, chemotherapy was given with a presumptive diagnosis of metastatic lung lesion. A good response was noted and, histologically, it was a primary lung cancer. In the third case, chemotherapy was given to a patient with obviously resectable lung carcinoma, and an excellent response was observed. According to the results, neoadjuvant chemotherapy for resectable NSCLC may be feasible and beneficial.
手术治疗仍然是局限性非小细胞肺癌(NSCLC)唯一的治愈性治疗方法。然而,手术治疗的结果仍有很大的改进空间。最近,Ⅲ期NSCLC的新辅助化疗已成为一种被认可的治疗方式。因此,对于可切除的NSCLC(Ⅰ期和Ⅱ期)进行新辅助化疗的可行性提出了一个问题。在本文中,我们按时间顺序报告了3例接受新辅助化疗的局限性NSCLC患者。第一例肺功能较差的患者接受了新辅助化疗。肿瘤大小的减小使他能够接受更保守的肺切除术。第二例患者在初步诊断为肺转移瘤时接受了化疗。观察到良好的反应,组织学检查显示为原发性肺癌。第三例患者患有明显可切除的肺癌,接受了化疗,并观察到极佳的反应。根据这些结果,可切除的NSCLC进行新辅助化疗可能是可行且有益的。